enow.com Web Search

  1. Ads

    related to: non alcoholic fatty liver medication fda approval

Search results

  1. Results from the WOW.Com Content Network
  2. US FDA approves first drug for fatty liver disease NASH - AOL

    www.aol.com/news/us-fda-approves-first-drug...

    (Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition ...

  3. FDA approves first drug for common form of liver inflammation

    www.aol.com/fda-approves-first-drug-common...

    The US Food and Drug Administration has approved the first medication for a common form of liver inflammation called nonalcoholic steatohepatitis, or NASH, the agency said Thursday.

  4. Madrigal Pharma surges after drug wins first approval for ...

    www.aol.com/news/madrigal-pharma-surges-fda-nod...

    (Reuters) -Madrigal Pharmaceuticals shares jumped as much as 23% on Friday after its oral drug became the first approved treatment for a fatty liver disease known as non-alcoholic steatohepatitis ...

  5. Resmetirom - Wikipedia

    en.wikipedia.org/wiki/Resmetirom

    The US Food and Drug Administration (FDA) evaluated the safety and efficacy of resmetirom based on an analysis of a surrogate endpoint at month twelve in a 54-month, randomized, double-blind placebo-controlled trial. [2] The surrogate endpoint measured the extent of liver inflammation and scarring. [2]

  6. Obeticholic acid - Wikipedia

    en.wikipedia.org/wiki/Obeticholic_acid

    Non-alcoholic steatohepatitis is a common cause of abnormal liver function with histological features of fatty liver, inflammation and fibrosis. It may progress to cirrhosis and is becoming an increasing indication for liver transplantation. It is increasing in prevalence. OCA is proposed to treat NASH. [21]

  7. Aramchol - Wikipedia

    en.wikipedia.org/wiki/Aramchol

    Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease. [1] [2] [3] [4]

  1. Ads

    related to: non alcoholic fatty liver medication fda approval